Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Apr;41(4):795–801. doi: 10.1128/aac.41.4.795

Treatment of experimental pneumonia due to penicillin-resistant Streptococcus pneumoniae in immunocompetent rats.

J Gavaldà 1, J A Capdevila 1, B Almirante 1, J Otero 1, I Ruiz 1, M Laguarda 1, H Allende 1, E Crespo 1, C Pigrau 1, A Pahissa 1
PMCID: PMC163797  PMID: 9087492

Abstract

A model of pneumonia due to Streptococcus pneumoniae resistant to penicillin was developed in immunocompetent Wistar rats and was used to evaluate the efficacies of different doses of penicillin, cefotaxime, cefpirome, and vancomycin. Adult Wistar rats were challenged by intratracheal inoculation with 3 x 10(9) CFU of one strain of S. pneumoniae resistant to penicillin (MICs of penicillin, cefotaxime, cefpirome, and vancomycin, 2, 1, 0.5, and 0.5 microg/ml, respectively) suspended in brain heart broth supplemented with 0.7% agar. The rats experienced a fatal pneumonia, dying within 5 days and with peak mortality (70 to 80%) occurring 48 to 72 h after infection, and the bacterial counts in the lungs persisted from 8.87 +/- 0.3 log10 CFU/g of lung at 24 h of the infection to 9.1 +/- 0.3 log10 CFU/g at 72 h. Four hours after infection the animals were randomized into the following treatment groups: (i) control without treatment, (ii) penicillin G at 100,000 IU/kg of body weight every 2 h, (iii) penicillin G at 250,000 IU/kg every 2 h, (iv) cefotaxime at 100 mg/kg every 2 h, (v) cefpirome at 200 mg/kg every 2 h, and (vi) vancomycin at 50 mg/kg every 8 h. Two different protocols were used for the therapeutic efficacy studies: four doses of beta-lactams and one dose of vancomycin or eight doses of beta-lactams and two doses of vancomycin. Results of the therapy for experimental pneumonia caused by penicillin-resistant S. pneumoniae showed that initially, all the antimicrobial agents tested had similar efficacies, but when we prolonged the treatment, higher doses of penicillin, cefotaxime, and cefpirome were more effective than penicillin at lower doses in decreasing the residual bacterial titers in the lungs. Also, when we extended the treatment, vancomycin was more efficacious than penicillin at lower doses but was less efficacious than higher doses of penicillin or cefpirome. The model that we have developed is simple and amenable for inducing pneumonia in immunocompetent rats and could be used to explore the pathophysiology and to evaluate optimal therapy of this infection in the immunocompetent host.

Full Text

The Full Text of this article is available as a PDF (844.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Appelbaum P. C. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infect Dis. 1992 Jul;15(1):77–83. doi: 10.1093/clinids/15.1.77. [DOI] [PubMed] [Google Scholar]
  2. Appelbaum P. C., Bhamjee A., Scragg J. N., Hallett A. F., Bowen A. J., Cooper R. C. Streptococcus pneumoniae resistant to penicillin and chloramphenicol. Lancet. 1977 Nov 12;2(8046):995–997. doi: 10.1016/s0140-6736(77)92892-6. [DOI] [PubMed] [Google Scholar]
  3. Azoulay-Dupuis E., Bedos J. P., Vallée E., Hardy D. J., Swanson R. N., Pocidalo J. J. Antipneumococcal activity of ciprofloxacin, ofloxacin, and temafloxacin in an experimental mouse pneumonia model at various stages of the disease. J Infect Dis. 1991 Feb;163(2):319–324. doi: 10.1093/infdis/163.2.319. [DOI] [PubMed] [Google Scholar]
  4. Azoulay-Dupuis E., Vallee E., Veber B., Bedos J. P., Bauchet J., Pocidalo J. J. In vivo efficacy of a new fluoroquinolone, sparfloxacin, against penicillin-susceptible and -resistant and multiresistant strains of Streptococcus pneumoniae in a mouse model of pneumonia. Antimicrob Agents Chemother. 1992 Dec;36(12):2698–2703. doi: 10.1128/aac.36.12.2698. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bakker-Woudenberg I. A., van den Berg J. C., Fontijne P., Michel M. F. Efficacy of continuous versus intermittent administration of penicillin G in Streptococcus pneumoniae pneumonia in normal and immunodeficient rats. Eur J Clin Microbiol. 1984 Apr;3(2):131–135. doi: 10.1007/BF02014330. [DOI] [PubMed] [Google Scholar]
  6. Barry A. L., Brown S. D., Novick W. J. In vitro activities of cefotaxime, ceftriaxone, ceftazidime, cefpirome, and penicillin against Streptococcus pneumoniae isolates. Antimicrob Agents Chemother. 1995 Oct;39(10):2193–2196. doi: 10.1128/aac.39.10.2193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Breiman R. F., Butler J. C., Tenover F. C., Elliott J. A., Facklam R. R. Emergence of drug-resistant pneumococcal infections in the United States. JAMA. 1994 Jun 15;271(23):1831–1835. [PubMed] [Google Scholar]
  8. Briles D. E., Crain M. J., Gray B. M., Forman C., Yother J. Strong association between capsular type and virulence for mice among human isolates of Streptococcus pneumoniae. Infect Immun. 1992 Jan;60(1):111–116. doi: 10.1128/iai.60.1.111-116.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Bédos J. P., Rolin O., Bouanchaud D. H., Pocidalo J. J. Relation entre virulence et résistance aux antibiotiques des pneumocoques. Apport des donnée expérimentales sur un modèle animal. Pathol Biol (Paris) 1991 Dec;39(10):984–990. [PubMed] [Google Scholar]
  10. Fantin B., Leggett J., Ebert S., Craig W. A. Correlation between in vitro and in vivo activity of antimicrobial agents against gram-negative bacilli in a murine infection model. Antimicrob Agents Chemother. 1991 Jul;35(7):1413–1422. doi: 10.1128/aac.35.7.1413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Feldman C., Kallenbach J. M., Miller S. D., Thorburn J. R., Koornhof H. J. Community-acquired pneumonia due to penicillin-resistant pneumococci. N Engl J Med. 1985 Sep 5;313(10):615–617. doi: 10.1056/NEJM198509053131006. [DOI] [PubMed] [Google Scholar]
  12. Fenoll A., Martín Bourgon C., Muñz R., Vicioso D., Casal J. Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates causing systemic infections in Spain, 1979-1989. Rev Infect Dis. 1991 Jan-Feb;13(1):56–60. doi: 10.1093/clinids/13.1.56. [DOI] [PubMed] [Google Scholar]
  13. Fernández Guerrero M. L., Arbol F., Verdejo C., Fernández Roblas R., Soriano F. Treatment of experimental endocarditis due to penicillin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother. 1994 May;38(5):1103–1106. doi: 10.1128/aac.38.5.1103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Friedland I. R., McCracken G. H., Jr Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med. 1994 Aug 11;331(6):377–382. doi: 10.1056/NEJM199408113310607. [DOI] [PubMed] [Google Scholar]
  15. Friedland I. R., Paris M., Ehrett S., Hickey S., Olsen K., McCracken G. H., Jr Evaluation of antimicrobial regimens for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother. 1993 Aug;37(8):1630–1636. doi: 10.1128/aac.37.8.1630. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Frimodt-Møller N., Bentzon M. W., Thomsen V. F. Experimental infection with Streptococcus pneumoniae in mice: correlation of in vitro activity and pharmacokinetic parameters with in vivo effect for 14 cephalosporins. J Infect Dis. 1986 Sep;154(3):511–517. doi: 10.1093/infdis/154.3.511. [DOI] [PubMed] [Google Scholar]
  17. Frimodt-Møller N., Bentzon M. W., Thomsen V. F. Experimental pneumococcus infection in mice: comparative in vitro and in vivo effect of cefuroxime, cefotaxime and ceftriaxone. Acta Pathol Microbiol Immunol Scand B. 1987 Oct;95(5):261–267. doi: 10.1111/j.1699-0463.1987.tb03123.x. [DOI] [PubMed] [Google Scholar]
  18. Gavaldà J., Cardona P. J., Almirante B., Capdevila J. A., Laguarda M., Pou L., Crespo E., Pigrau C., Pahissa A. Treatment of experimental endocarditis due to Enterococcus faecalis using once-daily dosing regimen of gentamicin plus simulated profiles of ampicillin in human serum. Antimicrob Agents Chemother. 1996 Jan;40(1):173–178. doi: 10.1128/aac.40.1.173. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Gerber A. U., Brugger H. P., Feller C., Stritzko T., Stalder B. Antibiotic therapy of infections due to Pseudomonas aeruginosa in normal and granulocytopenic mice: comparison of murine and human pharmacokinetics. J Infect Dis. 1986 Jan;153(1):90–97. doi: 10.1093/infdis/153.1.90. [DOI] [PubMed] [Google Scholar]
  20. Gerber A. U., Stritzko T., Segessenmann C., Stalder B. Simulation of human pharmacokinetic profiles in mice, and impact on antimicrobial efficacy of netilmicin, ticarcillin and ceftazidime in the peritonitis-septicemia model. Scand J Infect Dis Suppl. 1990;74:195–203. [PubMed] [Google Scholar]
  21. Hansman D., Glasgow H., Sturt J., Devitt L., Douglas R. Increased resistance to penicillin of pneumococci isolated from man. N Engl J Med. 1971 Jan 28;284(4):175–177. doi: 10.1056/NEJM197101282840403. [DOI] [PubMed] [Google Scholar]
  22. Jacobs M. R., Koornhof H. J., Robins-Browne R. M., Stevenson C. M., Vermaak Z. A., Freiman I., Miller G. B., Witcomb M. A., Isaäcson M., Ward J. I. Emergence of multiply resistant pneumococci. N Engl J Med. 1978 Oct 5;299(14):735–740. doi: 10.1056/NEJM197810052991402. [DOI] [PubMed] [Google Scholar]
  23. Knudsen J. D., Frimodt-Møller N., Espersen F. Experimental Streptococcus pneumoniae infection in mice for studying correlation of in vitro and in vivo activities of penicillin against pneumococci with various susceptibilities to penicillin. Antimicrob Agents Chemother. 1995 Jun;39(6):1253–1258. doi: 10.1128/aac.39.6.1253. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Liñares J., Alonso T., Pérez J. L., Ayats J., Domínguez M. A., Pallarés R., Martín R. Decreased susceptibility of penicillin-resistant pneumococci to twenty-four beta-lactam antibiotics. J Antimicrob Chemother. 1992 Sep;30(3):279–288. doi: 10.1093/jac/30.3.279. [DOI] [PubMed] [Google Scholar]
  25. Liñares J., Pallares R., Alonso T., Perez J. L., Ayats J., Gudiol F., Viladrich P. F., Martin R. Trends in antimicrobial resistance of clinical isolates of Streptococcus pneumoniae in Bellvitge Hospital, Barcelona, Spain (1979-1990). Clin Infect Dis. 1992 Jul;15(1):99–105. doi: 10.1093/clinids/15.1.99. [DOI] [PubMed] [Google Scholar]
  26. Marton A., Gulyas M., Munoz R., Tomasz A. Extremely high incidence of antibiotic resistance in clinical isolates of Streptococcus pneumoniae in Hungary. J Infect Dis. 1991 Mar;163(3):542–548. doi: 10.1093/infdis/163.3.542. [DOI] [PubMed] [Google Scholar]
  27. Mastro T. D., Ghafoor A., Nomani N. K., Ishaq Z., Anwar F., Granoff D. M., Spika J. S., Thornsberry C., Facklam R. R. Antimicrobial resistance of pneumococci in children with acute lower respiratory tract infection in Pakistan. Lancet. 1991 Jan 19;337(8734):156–159. doi: 10.1016/0140-6736(91)90813-5. [DOI] [PubMed] [Google Scholar]
  28. Moine P., Vallée E., Azoulay-Dupuis E., Bourget P., Bédos J. P., Bauchet J., Pocidalo J. J. In vivo efficacy of a broad-spectrum cephalosporin, ceftriaxone, against penicillin-susceptible and -resistant strains of Streptococcus pneumoniae in a mouse pneumonia model. Antimicrob Agents Chemother. 1994 Sep;38(9):1953–1958. doi: 10.1128/aac.38.9.1953. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Munoz R., Musser J. M., Crain M., Briles D. E., Marton A., Parkinson A. J., Sorensen U., Tomasz A. Geographic distribution of penicillin-resistant clones of Streptococcus pneumoniae: characterization by penicillin-binding protein profile, surface protein A typing, and multilocus enzyme analysis. Clin Infect Dis. 1992 Jul;15(1):112–118. doi: 10.1093/clinids/15.1.112. [DOI] [PubMed] [Google Scholar]
  30. Pallares R., Liñares J., Vadillo M., Cabellos C., Manresa F., Viladrich P. F., Martin R., Gudiol F. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med. 1995 Aug 24;333(8):474–480. doi: 10.1056/NEJM199508243330802. [DOI] [PubMed] [Google Scholar]
  31. Pennington J. E., Stone R. M. Comparison of antibiotic regimens for treatment of experimental pneumonia due to Pseudomonas. J Infect Dis. 1979 Dec;140(6):881–889. doi: 10.1093/infdis/140.6.881. [DOI] [PubMed] [Google Scholar]
  32. Powell M., McVey D., Kassim M. H., Chen H. Y., Williams J. D. Antimicrobial susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella (Branhamella) catarrhalis isolated in the UK from sputa. J Antimicrob Chemother. 1991 Aug;28(2):249–259. doi: 10.1093/jac/28.2.249. [DOI] [PubMed] [Google Scholar]
  33. Privitera G. Penicillin resistance among Streptococcus pneumoniae in Europe. Diagn Microbiol Infect Dis. 1994 Jul;19(3):157–161. doi: 10.1016/0732-8893(94)90059-0. [DOI] [PubMed] [Google Scholar]
  34. Spangler S. K., Jacobs M. R., Appelbaum P. C. Susceptibilities of 177 penicillin-susceptible and -resistant pneumococci to FK 037, cefpirome, cefepime, ceftriaxone, cefotaxime, ceftazidime, imipenem, biapenem, meropenem, and vancomycin. Antimicrob Agents Chemother. 1994 Apr;38(4):898–900. doi: 10.1128/aac.38.4.898. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Tateda K., Takashima K., Miyazaki H., Matsumoto T., Hatori T., Yamaguchi K. Noncompromised penicillin-resistant pneumococcal pneumonia CBA/J mouse model and comparative efficacies of antibiotics in this model. Antimicrob Agents Chemother. 1996 Jun;40(6):1520–1525. doi: 10.1128/aac.40.6.1520. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES